Insider Purchases: Inside the Buy
Tag: Growth Stocks
🎲 Flutter Entertainment (FLUT): Betting on the House at a 12x Discount
Flutter Entertainment (FLUT) has collapsed 69% from its highs, yet insiders are aggressively buying shares while FanDuel continues dominating U.S. sports betting. Is Wall Street underpricing one of the world’s most powerful gambling platforms?
🫀 Boston Scientific (BSX): A GARP Reset on a Medical Device Powerhouse
Boston Scientific stock has fallen nearly 48% from its highs, but the business engine remains strong. With double-digit revenue growth, major cardiovascular catalysts, director insider buying, low short interest, and a $2B buyback, BSX may be one of the cleaner large-cap healthcare GARP setups on the market.
🏗️ HubSpot (HUBS): From “Hubris” to “Hand-over-Fist”?
HubSpot (HUBS) just delivered strong Q1 2026 results, but the stock still plunged as investors questioned AI monetization, sales cycles, and valuation. With the CEO, founder-CTO, and director buying shares, institutions owning the float, revenue growing 23%, and valuation metrics finally looking reasonable, HUBS may be shifting from “growth at any price” to a serious GARP contender. 🏗️🤖📈
⚖️ LegalZoom (LZ): The “Lawsuit-Proof” Balance Sheet?
LegalZoom (LZ) is becoming one of the most fascinating battleground stocks of 2026. With the CEO buying shares for the first time, institutions owning more than 100% of float, elevated short interest, and a debt-free balance sheet generating real free cash flow, bulls believe the legal-tech platform could be dramatically undervalued. Bears counter that AI could commoditize core services. At roughly 70% below all-time highs, the courtroom battle is officially underway. ⚖️🚀
🚀 Upstart Stock: Founder Buys $5M as AI Lending Underdog Faces Short-Squeeze Setup
Upstart stock is back in Wall Street’s drama zone: insider buying, massive short interest, AI lending growth, cash-flow concerns, and a possible bank-charter catalyst. High risk? Absolutely. Boring? Not even close.
CEO Bets $11.9M: Is Oscar Health (OSCR) About to Shock the Market? 🚀
Oscar Health (OSCR) is no longer just a flashy disruptor—it’s aiming for profitability. With CEO Mark Bertolini buying $11.9M in stock and revenue projected to hit $19B in 2026, this could be one of the most compelling turnaround plays in healthcare.
Phreesia (PHR): Profitable… Then Crushed — Why Insiders Are Loading Up
Phreesia just hit profitability—and got punished for it. With insiders loading up and institutions fully committed, is this a classic overreaction or a value trap? Let’s decode the dip.
Lululemon (LULU): 68% Off — Bargain or Value Trap? 🧘
Lululemon (LULU) has fallen sharply from its highs, but insider buying and international growth suggest opportunity. Is this a contrarian buy—or a value trap in disguise?
CORT Stock 2026: FDA Rejection, Insider Buying… and a Brewing Short Squeeze?
Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.
SFM Stock Analysis 2026: Is Sprouts Farmers Market a Short Squeeze or a Value Trap?
Sprouts Farmers Market stock has fallen sharply from its 2025 highs, yet the company continues to grow sales, generate strong profits, and buy back shares. With insider buying and heavy institutional ownership, the setup is intriguing.